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This paper presents an atypical case of a patient with brain tumor of the glioblastoma mul-
tiforme (GBM) type who achieved a 5-year survival. Some general information is provided
including epidemiology, diagnostic and treatment procedures (surgery and radio-chemo-
therapy), and prognosis of survival related to GBM. The course of the disease, including its
main  symptoms, individual reasons for the delay of adjuvant treatment, after the primary
surgical treatment, 37-month period of the decease free survival, as well as comprehensive
management after the tumor recurrence are also presented. Histopathology conﬁrming thelioblastoma
urvival
rain tumors
reatment
adiotherapy
clinical diagnosis is discussed in a separate chapter.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
the application of novel radiosensitizers of corpuscular irradi-.  Background
rimary brain tumors account for about 2% of all malignant
eoplasms in adults. Approximately a half of them repre-
ent gliomas, derived from neuroepithelial cells, among which
lioblastoma (GBM) is the most common type.
GBM cases represent about 20% of all primary brain tumors
n the adult population, and about 75% of all the anaplas-
1ic gliomas. The prevalence of GBM is about 2–4 cases per
00,000. It is more  common in men  than in women, and its
ncidence increases with age.2 Only sporadically, GBM can be
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frequency rapidly increases, starting from the 5-th decade of
life.
The treatment results of patients diagnosed with GBM
are often unsatisfactory, and the outcome is usually poor.
Currently, the main standard therapeutic methods include
a radical surgical procedure, combined with radio-chemo-
therapy. Some innovative methods of radiotherapy based onowskiej-Curie, Oddział w Gliwicach, Zakład Radioterapii, 44-101
om (H. Urban´czyk).
ation or radio-immune-therapy are now being investigated. A
median survival time of patients diagnosed with GBM, treated
only with the use of neurosurgical procedures are 3–5 months.
rban & Partner Sp. z o.o. All rights reserved.
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The application of conventional adjuvant radiotherapy pro-
longs this average time about 3-fold, with a three-year survival
for only about 6% of patients.
The post-treatment survival time depends on many  clin-
ical factors, such as general patient condition, age, and
histopathological type of the tumor. Simson et al. demon-
strated statistically signiﬁcant longer survival periods among
patients in whom the primary tumor location was in the
frontal lobe, in comparison to the ones in whom it was located
in the parietal or temporal cerebral region (11.4 months vs.
9.6 months vs. 9.1 months, respectively; p = 0.01).3 Severity
of neurological symptoms, limits of the performed surgical
procedures, and response to the applied therapy, based on
imaging tests, also represent prognostic factors.
Etiology of malignant neoplasms of the central ner-
vous system (CNS) is still unknown. The most common of
many probable carcinogens include: nitrosamines, pesticides,
herbicides, petrochemical substances, polyvinyl chloride, and
electromagnetic irradiation. However, the role of these pro-
carcinogenic factors has not been unequivocally proven.4,5 In
contrast, it has been documented that patients exposed to
ionizing irradiation have an increased risk of the CNS malig-
nant gliomas. According to the current state of knowledge in
the ﬁeld of molecular biology and genetics of these malignan-
cies, two main hypotheses related to their development have
been proposed. The ﬁrst one includes de novo creation which
is related to the loss of heterozygotic properties in chromo-
somes 9p, 10, 17p, and with the ampliﬁcation of genes for the
EGFR and CDK4 (this type of malignant growth occurs more
often in older patients). The second one involves the creation
of anaplastic gliomas, through the progression of gliomas with
a lower malignancy grade (encountered more  often in younger
patients).6,7
Currently, a required standard of therapy for patients with
GBM is a combined treatment, including tumor resection,
with following concomitant radio-chemo-therapy, and adju-
vant chemo-therapy, based on Temozolomide. In patients
who  undergo non-radical surgery, or who are not treated
surgically, the palliative whole brain radiotherapy (WBRT),
stereotactic radiation surgery (SRS), or combination of both
of these therapeutic methods are used. Also, the applica-
tion of palliative chemotherapy and symptomatic treatment
remain important. In addition, alternatively fractionated
radiotherapy, brachytherapy, targeted molecular therapy,
radio-immune-therapy, hadrone therapy, or radio-sensitizers
can be considered in individual cases.
In 2005, Stupp et al. presented results of a randomized
study conducted by EORTC (European Organization for Research
and Treatment of Cancer)  and NCIC (National Cancer Institute of
Canada), comparing the application of combined radio-chemo-
therapy based on Temozolomide and radical radiotherapy
alone. The combined management in a statistically signiﬁcant
manner prolonged the total survival time from 12.1 to 14.6
months, and the rate of 2-year survival was 26.5%, compared
to 10.4% for radiotherapy alone.8 The follow-up results, after a
longer period of observation, conﬁrmed the previous reports.
The 2-, 3-, and 4-year survival rates were 27.3%, 16.7%, and
12.9%, respectively (p < 0.0001) in the patients’ group treated
with a combined therapy, and 11.2%, 4.3%, and 3.8%, in the
patients’ group treated with radiotherapy only.9iotherapy 1 9 ( 2 0 1 4 ) 347–351
Unfortunately, despite the use of Temozolomide, the
results are unsatisfactory. The reason for this therapeutic fail-
ure is the GBM resistance to most chemotherapeutic agents
or rapid development of the GBM as a result of genetic trans-
formations within the tumor cells. The main mechanism of
the GBM resistance to alkylating agents, such as temozolo-
mide, procarbazine, or nitrogen mustard derivatives, is the
repair of damages caused by these drugs with involvement
of protein coded by MGMT (O6-methyl-guanine-DNA methyl-
transferase) gene.
A degree of methylation of the promoter’s region of MGMT
gene appears to be closely correlated with a therapeutic
response of the glioma cells. Hypermethylation of this part
of the gene signiﬁcantly increases treatment efﬁcacy among
patients treated with Temozolomide,10 inﬂuencing their sur-
vival period, as well.9
2.  Case  presentation
The patient is a 38 year old Caucasian male, smoker (about
10–15 cigarettes per day for 20 years), without other relevant
family or personal risk factors for neoplasic disease who  had
suffered from severe headaches and nausea (his ﬁrst disease
symptoms) since August of 2005. He did not seek any medical
help until November of 2005, when he presented to his doctor,
due to exacerbation of those symptoms. No abnormalities on
both physical and neurological examinations were detected at
that time.
On December 30th of 2005, the CT scan of his brain
was remarkable for the following ﬁndings: “An expansive
lesion of approximately 5 cm × 3 cm in size, located in the
right temporal lobe, with nonhomogenic, post-contrast signal
ampliﬁcation. A large edema surrounding the lesion. A com-
pression of the occipital corner of the right lateral ventricle. A
slight enlargement of the supratentorial ventricular system,
shifting to the left.”
On January 25th of 2006, the patient underwent surgi-
cal therapy, including right temporal craniotomy, with total
resection of the tumor. On February 7th of 2006, a histopath-
ology examination (identiﬁcation number 475,958; Info-Pat,
Poznan´, Poland), conﬁrmed a diagnosis of the GBM IV stage
(according to WHO  classiﬁcation). Microscopic images of the
tumor are presented (Figs. 1–5).
After the surgery, the patient was referred to the Institute of
Radiation Oncology in Gliwice, Poland, for the post-operative
radiotherapy. Although the patient was qualiﬁed for this treat-
ment, he did not arrive to the Institute of Radiation Oncology
on the day of the scheduled preparatory procedures. The rea-
son for his absence was a simultaneous diagnostic ﬁnding
of the left lung’s tumor, for which the patient underwent a
thoracotomy with the wedge tumor resection (for diagnostic
purposes). On June 12th of 2006, based on the histopatho-
logical examination results, which showed post-tuberculosis
lesions, the patient’s pulmonary treatment was completed.
In February 2007, approximately 13 months after his brain
tumor surgery, the patient again presented to the Institute of
Oncology, and according to the follow-up diagnostic work-up,
no brain tumor recurrence was found. Due to the absence
of tumor, no radiotherapy was considered, and “watchful
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Fig. 1 – Microscopic image of patient’s tumor.
Fig. 2 – Microscopic image of patient’s tumor.
Fig. 3 – Microscopic image of patient’s tumor.
Fig. 4 – Microscopic image of patient’s tumor.Fig. 5 – Microscopic image of patient’s tumor.
waiting” was recommended including brain imaging studies
(CT or MRI) to be repeated every 3 months. In the face of
the atypical disease course, an additional veriﬁcation of the
histopathological diagnosis was also performed, conﬁrming
the original ﬁndings of the GBM. The patient had remained
under close control until February 2009 (37 months from his
initial brain tumor surgery), and at that time the brain tumor
recurrence was found. His recurrent tumor was located in the
primary tumor’s bed, and its size was 4 cm × 5.3 cm × 3.5 cm
(Fig. 6). However, those ﬁndings were not associated with any
particular symptoms or abnormalities on subsequent phys-
ical or neurological examinations of the patient. On March
16th 2009, the patient underwent another craniotomy with
the subtotal tumor resection. (MRI scans after the second
craniotomy are shown in Figs. 7 and 8.) The histopatho-
logy examination was again consistent with GBM. During the
period from May 11th to June 19th of 2009, the patient received
the radiotherapy dose of 60 Gy/30 fractions to the tumor lodge,
including the residual tumor, with 2.5 cm of tissue margin.
Due to the lack of the patient’s consent, no chemotherapy
was implemented. During the irradiation period, he had the
ﬁrst seizure episode, and was started on antiepileptic therapy
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Fig. 6 – CT scan of recurrence tumor. Fig. 8 – MRI  scan after the second craniotomy.Fig. 7 – MRI  scan after the second craniotomy.
(Depakine 200 mg  a day). He continued this therapy for the rest
of his life. After the radiotherapy, diagnostic follow-up exam-
inations were conducted every 3 months. At the beginning of
March 2010, another recurrence was found, and the tumor was
localized in an upper part of the tumor bed, within the pre-
viously irradiated area (its size was 3.7 cm × 2.6 cm × 2.3 cm).
Surprisingly, the patient had not experienced any symp-
toms, and his physical and neurological examinations were
unremarkable. On March 13th of 2010, the stereotactic radio-
therapy, using a single dose of 8 Gy applied to the area of
recurrent tumor was performed. Unfortunately, on the con-
trol examination, on July 6th of 2010, further progression ofthe GBM was found. The patient expired on November 15th
of 2010, in the local hospital (Zawiercie, Poland), due to the
tumor expansion, resulting in cerebral edema, herniation, and
multi-organ failure.
3.  Histopathology  examination
On a histopathology specimen, the large areas of throm-
botic necrosis, most probably caused by a large tumor size
(5 cm × 3 cm)  were found. In contrast, no “palisade” necrosis
(with the characteristic palisade-like cell arrangements), typ-
ical for this type of tumor, was found.
Within vital tumor structures, a high cellular poly-
morphism was found. Besides some small calls (with
hyperchromatic nucleus and scarce amount of cytoplasm),
mostly atypical cells (giant, multisided or oval, with numer-
ous nuclei with abnormal shapes, and visible nucleoli) were
present. The cells revealed a strongly positive GFAP reaction
that can be indicative of their glioma-type origin. Also, some
distinctive GBM features, including proliferation of vascular
endothelium (focal areas of numerous mitotic ﬁgures, in high
power ﬁeld – HPF), were visible. The described microscopic
images are presented in Figs. 1–5 (the images of primary and
recurrent tumors appear identical).
4.  Summary
In this paper, we  presented a remarkably long survival period
(63 months since the initial onset of symptoms, and 58 months
since the primary surgical treatment) of the GBM patient. An
important message from our case study that could be useful
in the management of many  other GBM cases is that the initial
complete resection suggests a beneﬁcial role of radical
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alone. Rad Oncol Biol Phys 2007;69:S2.reports of practical oncology and 
eurosurgery in the early GBM treatment and potential sur-
ival period.
Unfortunately, we  are unable to indicate the speciﬁc rea-
ons for such a long survival of our relatively asymptomatic
atient who experienced some disadvantages, including the
econd malignancy, which caused the delay in the application
f his radiotherapy.
Nevertheless, it should be emphasized that personalized,
atient-centered approach, using comprehensive diagnostic
nd therapeutic strategies, as well as vigilant, multi-level
ollow-up care, should be helpful in explaining different
actors, contributing to overall survival. In addition, our sin-
le case presentation illustrates several challenges that are
ommon to many  GBM patients, and merit further, more  indi-
idualized research on this devastating disease.
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